Understanding how changes in sugar molecules affect cancer progression
Toward understanding the role of altered glycosylation in cancer
This study is looking at how changes in sugar molecules on proteins might help cancer cells avoid the immune system, and it aims to find ways to boost the immune response against cancer, which could be helpful for patients undergoing treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11092110 on NIH RePORTER |
What this research studies
This research investigates the role of altered glycosylation, which refers to changes in sugar molecules attached to proteins, in the progression of cancer. By using advanced techniques in glycoproteomics, biochemistry, and bioinformatics, the study aims to uncover how these changes contribute to immune evasion in tumors. The research focuses on a specific protein called TIM3, which is involved in immune signaling and may play a role in cancer immunotherapy. Patients may benefit from insights gained about how to enhance immune responses against cancer by targeting these glycan changes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that may be influenced by immune evasion mechanisms.
Not a fit: Patients with non-cancerous conditions or those whose cancers are not related to glycosylation changes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer immunotherapy strategies that enhance the body's ability to fight cancer.
How similar studies have performed: Other research has shown promise in understanding glycosylation's role in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Malaker, Stacy Alyse — Yale University
- Study coordinator: Malaker, Stacy Alyse
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.